Already competing to bring the first vaccine against respiratory syncytial virus (RSV) to market, Pfizer and GSK are also fighting a patent infringement battle in the courts. Earlier this month ...

(Reuters) - GSK and Pfizer's respiratory syncytial virus (RSV) vaccines will carry warnings that they can increase the risk of developing a rare neurological disorder, the U.S. Food Drug ...

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

Respiratory syncytial virus prefusion F (RSVpreF ... This study was funded by Pfizer. Several authors declared receiving grants and personal fees from Pfizer paid to the institution outside ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

A virus rapidly spreading in China is also circulating in the United States, causing concern among health experts.

For most people RSV is like a cold, but for infants and older people it can lead to serious infections. Here's what to know.

Pfizer said it will 'support capacity-building initiatives, such as training healthcare professionals and advancing clinical ...